White Flower Analgesic is made from a traditional blend of aromatic herbs such as lavender and mint, which eases headaches and minor pains made worse from poor circulation, inclement weather, or unwise dietary habits and addictions. White Flower analgesic oil or balm can be inhaled to help clear sinus congestion.

Tiger Balm Ultra Strength Pain Relief Ointment (White, non-staining) contains the highest concentration of ingredients of each of the balms which includes camphor, mint, cinnamon, cajuput, clove and menthol which help relieve muscular aches and pains, soothe tired muscles, increase circulation in arthritic joints, warm up muscles before exercise and ease soreness after working out. Sports Rub for sore muscles and overexertion. Tiger Balm has been used by over one-third of the world’s population for over 100 years. It is an effective external analgesic rub. Today, over 20 million jars of Tiger Balm are sold annually in over 70 countries. Tiger Balm is made from the finest ingredients. Tiger Balm concentrated formulation penetrates quickly and provides effective temporary relief.

The Roots of Healing: A Woman’s Book of Herbs by Deb Soule and Susan Szwed

Oxidative stress and aging is a multi-dimensional/factorial subject matter encompassing different degrees of organism complexity (from single-cell animals to humans), different molecules (DNA, RNAs, proteins and lipids), different cellular components (mitochondria, cytoplasm and plasma membrane), different tissues and organs, and different human subpopulations including those with different “lifestyles.” This book roughly follows this complexity hierarchy, from molecules to organisms; and within each section, pro- and anti-oxidant components will be presented and human implications will be discussed. Some overlap in coverage of topics is anticipated and this is deemed both necessary and preferable for the existing literature is often controversial. The book concludes with a chapter focusing on possible lifespan extension strategies based on our understanding of oxidative stress protection. A short preface in each of the major sections will be included to summarize the section and briefly mention other topics not specifically covered by the chapters within. The following chapter titles are tentative and will be adjusted according the contributors’ preferences.

This book will provide up-to-date practical information in a form that is readily accessible and clinically relevant. It will be distinguished from other resources available by innovative use of graphics to convey data such as drug mechanisms and class differences. Also distinguishing it will be the use of clinical examples to demonstrate the nuanced treatment approaches of master clinicians in the field.

Section One will focus on essential information for clinicians prescribing any psychotropic medication. Several significant clinical and forensic areas will be covered. First, the necessary components of a thorough psychopharmacologic evaluation will be outlined. Second, legal matters salient for psychotropic prescribing will be addressed, including the important issue of off-label prescribing. Third will be a section dealing with communicating with parents regarding medications, including practical tips for administering and monitoring doses. Finally, a discussion of suicidality will include the evaluation of the suicidal patient as well as a thoughtful approach to the timely issue of suicidality and psychotropic medications, including an approach to the new FDA black box warnings.

Section Two will detail each of the commonly prescribed psychotropic medications. Emphasis will be placed on practical clinical issues such as dosing (starting dose, titration schedule, maximum dose), side effects, recommended monitoring schedule (e.g., vital signs, labs, ECGs, drug levels), and common drug interactions. This section will feature use of creative graphical displays to make dense material easily accessible. Photographs of medications will contribute an additional dimension to this section.

Section Three will discuss the psychopharmacologic treatment of each of the major classes of disorders. For each disorder, the current data and practice recommendations will be presented. Case examples and clinical pearls will make the material salient and will help convey the treatment approaches of master clinicians who approach complex patients with both rigor and creativity.

The book will be targeted to clinicians treating children with psychiatric disorders, including child and adolescent psychiatrists, pediatricians, family physicians, and pediatric neurologists, as well as residents in these fields, and medical students. Other target audience members include other mental health practitioners including psychologists and social workers that treat patients on psychotropic medications, and psychiatric nurses who may prescribe or monitor medications. Emergency room physicians may encounter children taking psychiatric medications and would benefit from an accessible source of information. Additionally, although the book will be targeted toward health care practitioners, the parents and teachers of children with psychiatric disorders may find this book a useful reference.

In the second edition of this well-known, comprehensive title on Alzheimer’s Disease, prominent Alzheimer’s investigators from throughout the world provide an updated and expanded overview of therapeutics for this devastating disease. Divided into five parts, the book begins with basic research on the neurobiology of cognitive function, offering relevant information on the way the brain encodes and stores data. The second segment covers epidemiology, including the global economic burden and risk factors for developing AD. Section three, greatly expanded from the first edition, explores the full range of issues involved in clinical assessment, while sections four and five cover the transitional stage and treatment options, respectively.

In this text, Andrew Cooper presents an original perspective on the relationship between psychotherapeutic thinking and practice, and knowledge of society and social processes. Drawing on a wide range of theoretical, clinical and sociological traditions this book evaluates their inter-connections and discontinuities in search of a distinctive appreciation of how the clinical mind and the sociological imagination can fertilise one another. This synthesis is developed to inform our orientation to both the world of evidence-based practice and the emergence of a ‘therapeutic culture’.

The Neurologist’s Guide to Pain: A Case-based Approach (Current Clinical Neurology)

The molecule, CXCR4, is part of a large family of proteins called G-protein coupled receptors (GPCRs). These molecules span the cell’s membrane and transmit signals from the external environment to the cell’s interior. GPCRs help control practically every bodily process, including cell growth, hormone secretion and light perception. Nearly half of all drugs on the market target these receptors.

“Scientists have been studying CXCR4 for years but have only been able to guess at what it looks like,” said NIH Director Francis S. Collins, M.D., Ph.D. “Now that we have its structure, we have a much clearer picture of how this medically important molecule works, opening up entire new areas for drug discovery.”

The researchers, led by Raymond C. Stevens, Ph.D., of the Scripps Research Institute in La Jolla, Calif., report their findings in the Oct. 7, 2010, advance online issue of the journal Science. The study received support from two major NIH initiatives: the structural biology program of the NIH Common Fund and the Protein Structure Initiative (PSI).

While a molecule called CD4 is the primary receptor for HIV, CD4 is not sufficient for the virus to penetrate cells. In 1996, a team of researchers at NIH’s National Institute of Allergy and Infectious Diseases (NIAID) discovered that CXCR4 acts as a co-receptor by helping HIV enter cells.

Normally, CXCR4 helps activate the immune system and stimulate cell movement. But when the signals that activate the receptor aren’t properly regulated, CXCR4 can spur the growth and spread of cancer cells. To date, CXCR4 has been linked to more than 20 types of cancer.

The Scripps Research scientists set out to shed light on how CXCR4 functions by capturing snapshots of the protein by using a structure determination method called X-ray crystallography. To understand how natural molecules might bind and signal through the receptor and to see how potential drugs could interact with it, they examined CXCR4 bound to known inhibitors of its activity.

Determining the structure of CXCR4 represented a major challenge because membrane proteins are notoriously tricky to coax into the crystal form required for the X-ray technique. After three years of optimizing conditions for producing, stabilizing and crystallizing the molecule, the scientists finally generated five distinct structures of CXCR4.

The structures showed that CXCR4 molecules form closely linked pairs, confirming data from other experiments indicating that pairing plays a role in the proper functioning of the receptor. With this knowledge, scientists can delve into how the duos might regulate CXCR4’s activity and better understand how CXCR4 functions under normal and disease conditions.

The images also showed that CXCR4 is shaped like two white wine glasses touching in a toast, with the inhibitors bound at the sides of the bowls. By detailing these contacts, the researchers said the pictures suggest how to design compounds that regulate CXCR4 activity or block HIV entry into cells. If developed into drugs, such compounds could offer new ways to treat HIV infection or cancer.

“An approach to determining protein structures that was developed with support from the NIH Common Fund and the PSI is now paying huge dividends,” said Jeremy M. Berg, Ph.D., director of the National Institute of General Medical Sciences, which supports the PSI. “It illustrates how technical progress provides a foundation for rapid advances, and it also showcases the benefits of collaborations between structural biologists and scientists working in other fields for addressing fundamentally important problems with tremendous potential for medical applications.”

The research also was supported by NIAID and the National Center for Research Resources, also part of NIH.

To arrange an interview with NIGMS Director Jeremy M. Berg, Ph.D., or Ward Smith, Ph.D., director of the NIGMS Protein Structure Initiative, contact the NIGMS Office of Communications and Public Liaison at 301-496-7301. For more information about the NIGMS Protein Structure Initiative, go to http://www.nigms.nih.gov/Initiatives/PSI/.

NIGMS is a part of NIH that supports basic research to increase our understanding of life processes and lay the foundation for advances in disease diagnosis, treatment and prevention. For more information on the Institute’s research and training programs, see http://www.nigms.nih.gov.

NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

NCRR provides laboratory scientists and clinical researchers with the resources and training they need to understand, detect, treat and prevent a wide range of diseases. NCRR supports all aspects of translational and clinical research, connecting researchers, patients and communities across the nation. For more information, visit www.ncrr.nih.gov.

The NIH Common Fund encourages collaboration and supports a series of exceptionally high impact, trans-NIH programs. The Structural Biology Program is funded through the Common Fund, and managed by the NIH Office of the Director in partnership with the various NIH Institutes, Centers and Offices. Common Fund programs are designed to pursue major opportunities and gaps in biomedical research that no single NIH Institute could tackle alone, but that the agency as a whole can address to make the biggest impact possible on the progress of medical research. Additional information about the NIH Common Fund can be found at http://commonfund.nih.gov.

The National Institutes of Health (NIH) — The Nation’s Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.